Please login to the form below

Not currently logged in
Email:
Password:

SMC: Celgene's Abraxane 'too expensive' for Scotland

But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta

Celgene Abraxane pancreatic cancerPancreatic cancer patients in Scotland should not have NHS access to Celgene's Abraxane, according to guidance from the Scottish Medicines Consortium (SMC).

The decision was one of several published yesterday by the SMC, which assesses the cost-effectiveness of new treatments for use by the NHS in Scotland.

Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol) and Gilead Science's fast-growing hepatitis C treatment Sovaldi (sofosbuvir).

Regarding Abraxane (paclitaxel albumin), the SMC's full guidance states that it does not recommend the drug in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. This is one of the drug's two approved EU indications, the other being metastatic breast cancer.

The SMC did acknowledge the drug's benefits in patients with pancreatic cancer, with clinical data demonstrating it can improve overall survival by 1.8 months compared with treatment with gemcitabine alone.

However, the watchdog said that the cost-effectiveness of the medicine was “above the threshold that is normally accepted”.

The decision was challenged by the charity Pancreatic Cancer UK whose CEO Alex Ford said it was “bad news for metastatic pancreatic cancer patients in Scotland”.

Ford added that it was “especially distressing” as Abraxane is available in England via the Cancer Drugs Fund - a fund set up by the government specifically to pay for cancer drugs not available for NHS reimbursement.

Celgene is currently trying obtain NHS reimbursement status for Abraxane in England and Wales and has submitted the drug for review by the National Institute for Health and Care Excellence (NICE), the SMC equivalent for the NHS in England and Wales. NICE guidance is expected in the autumn.

Article by
Thomas Meek

10th June 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics